WHO ICTRP trial
A randomized, double-blind, placebo-controlled, alternating panel single…
NL-OMON48530 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON48530 |
|---|---|
| Public title | A randomized, double-blind, placebo-controlled, alternating panel single ascending dose, sequential multiple ascending dose, and food effect study of FM101 in healthy male and female volunteers |
| Scientific title | A randomized, double-blind, placebo-controlled, alternating panel single ascending dose, sequential multiple ascending dose, and food effect study of FM101 in healthy male and female volunteers - FM101 SAD/MAD/FE Study |
| Primary sponsor | Future Medicine Co., Ltd. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | NAFLD NASH;10018307;10019654;NAFLD;NASH |
| Interventions | Part A: FM101 or placebo will be given as a drink. The volume of this drink will depend on the doses but will not be more than 240 mL. Depending on the dose you will receive, the study compound will be given to you in a dispenser (syringe)… |
| Registration date | Aug 1, 2019 |
| Target size | 50 |
| Secondary IDs | 2018-004298-28;NL68308.056.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: